[{"id":"33062010-2f9f-457a-bb48-293b21b77b51","acronym":"RAGNAR","url":"https://clinicaltrials.gov/study/NCT04083976","created_at":"2021-01-18T19:59:45.508Z","updated_at":"2025-02-25T12:37:25.290Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","source_id_and_acronym":"NCT04083976 - RAGNAR","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR2 • FGFR • TACC3 • TACC2","pipe":" | ","alterations":" FGFR3 mutation • FGFR mutation • FGFR fusion","tags":["FGFR2 • FGFR • TACC3 • TACC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation • FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 11/20/2019","start_date":" 11/20/2019","primary_txt":" Primary completion: 12/04/2023","primary_completion_date":" 12/04/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"9480eee5-c88d-4aa5-a04a-bfe171590b90","acronym":"INCB 84344-102","url":"https://clinicaltrials.gov/study/NCT03934372","created_at":"2021-01-18T19:22:38.750Z","updated_at":"2025-02-25T14:40:12.243Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","source_id_and_acronym":"NCT03934372 - INCB 84344-102","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" FLT3 • ABL1 • BCR • RET • FGFR • BLM","pipe":" | ","alterations":" EGFR mutation • KIT mutation • FGFR mutation • RET mutation","tags":["FLT3 • ABL1 • BCR • RET • FGFR • BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KIT mutation • FGFR mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-14"},{"id":"ab21b4e4-b3ac-475c-9005-48c011e2a7c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05316155","created_at":"2022-04-07T12:57:01.192Z","updated_at":"2025-02-25T15:27:19.690Z","phase":"Phase 1/2","brief_title":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","source_id_and_acronym":"NCT05316155","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • erdafitinib intravesical delivery system (TAR-210)"],"overall_status":"Recruiting","enrollment":" Enrollment 262","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 03/30/2028","primary_completion_date":" 03/30/2028","study_txt":" Completion: 09/19/2029","study_completion_date":" 09/19/2029","last_update_posted":"2025-02-10"},{"id":"b88cc8bc-838d-43e3-8862-07db1c3a612f","acronym":"SWOG-S1318","url":"https://clinicaltrials.gov/study/NCT02143414","created_at":"2021-01-18T09:57:21.812Z","updated_at":"2025-02-25T16:36:22.860Z","phase":"Phase 2","brief_title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02143414 - SWOG-S1318","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R","pipe":" | ","alterations":" ABL2 fusion","tags":["ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine delayed release (DR6MP) • mercaptopurine • Xatmep (methotrexate oral solution)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 10/23/2025","study_completion_date":" 10/23/2025","last_update_posted":"2025-02-06"},{"id":"0d8f1ed3-a22c-48e1-aa44-43808dd8c739","acronym":"","url":"https://clinicaltrials.gov/study/NCT04595747","created_at":"2021-01-19T20:29:57.852Z","updated_at":"2025-02-25T16:53:20.251Z","phase":"Phase 2","brief_title":"Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)","source_id_and_acronym":"NCT04595747","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rogaratinib (BAY 1163877)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/03/2021","start_date":" 05/03/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2025-02-04"},{"id":"25d363db-b73d-42b4-a08a-717568224b15","acronym":"THOR-2","url":"https://clinicaltrials.gov/study/NCT04172675","created_at":"2021-01-18T20:21:16.432Z","updated_at":"2025-02-25T17:00:18.386Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","source_id_and_acronym":"NCT04172675 - THOR-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Balversa (erdafitinib) • mitomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 07/12/2024","primary_completion_date":" 07/12/2024","study_txt":" Completion: 03/03/2025","study_completion_date":" 03/03/2025","last_update_posted":"2025-02-03"},{"id":"f228ffce-69d8-4696-a61e-6222a211f51d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188508","created_at":"2022-01-12T14:53:32.609Z","updated_at":"2025-02-25T16:17:09.399Z","phase":"Phase 2","brief_title":"Pembrolizumab, Olaparib, and Temozolomide for People with Glioma","source_id_and_acronym":"NCT05188508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type","tags":["EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"7bb8b08e-5d1b-431b-b5ae-8689cf85f453","acronym":"","url":"https://clinicaltrials.gov/study/NCT05656235","created_at":"2024-01-16T22:19:54.900Z","updated_at":"2025-02-25T15:36:00.703Z","phase":"Phase 2","brief_title":"Renal Retention in High Grade Upper Tract Urothelial Cancer","source_id_and_acronym":"NCT05656235","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/25/2024","start_date":" 11/25/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-12-11"},{"id":"0b4bc025-bfab-4d27-a83b-163254f008e0","acronym":"CR109248","url":"https://clinicaltrials.gov/study/NCT05567185","created_at":"2022-10-05T13:56:18.093Z","updated_at":"2024-07-02T16:35:02.053Z","phase":"Phase 1","brief_title":"A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer","source_id_and_acronym":"NCT05567185 - CR109248","lead_sponsor":"Janssen Pharmaceutical K.K.","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erdafitinib intravesical delivery system (TAR-210)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 10/16/2026","primary_completion_date":" 10/16/2026","study_txt":" Completion: 09/24/2027","study_completion_date":" 09/24/2027","last_update_posted":"2024-05-22"},{"id":"36d108df-7220-49ba-9e5c-6bcdaeaf319d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04092673","created_at":"2021-01-18T20:01:41.284Z","updated_at":"2024-07-02T16:35:02.263Z","phase":"Phase 1/2","brief_title":"Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies","source_id_and_acronym":"NCT04092673","lead_sponsor":"Effector Therapeutics","biomarkers":" KRAS • FGFR • CCND1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • HER-2 negative • KRAS G12 • FGFR amplification","tags":["KRAS • FGFR • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • HER-2 negative • KRAS G12 • FGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Verzenio (abemaciclib) • Lumakras (sotorasib) • fulvestrant • zotatifin (eFT226)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/25/2019","start_date":" 10/25/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-05-21"},{"id":"1724693c-3f92-4147-a8fc-47d82f80159d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04742959","created_at":"2023-12-01T18:15:51.667Z","updated_at":"2024-07-02T16:35:07.274Z","phase":"Phase 1/2","brief_title":"Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04742959","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • tinengotinib (TT-00420)"],"overall_status":"Completed","enrollment":" Enrollment 203","initiation":"Initiation: 03/14/2021","start_date":" 03/14/2021","primary_txt":" Primary completion: 02/20/2024","primary_completion_date":" 02/20/2024","study_txt":" Completion: 02/20/2024","study_completion_date":" 02/20/2024","last_update_posted":"2024-04-26"},{"id":"e391f2a5-896d-4821-b066-fdd97cba862d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04919642","created_at":"2021-06-10T01:52:34.634Z","updated_at":"2024-07-02T16:35:07.347Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma","source_id_and_acronym":"NCT04919642","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinengotinib (TT-00420)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-04-26"},{"id":"07a51dc9-114c-48cd-acba-f59680179bb5","acronym":"INNATE","url":"https://clinicaltrials.gov/study/NCT04669899","created_at":"2021-07-23T15:52:37.047Z","updated_at":"2024-07-02T16:35:10.864Z","phase":"Phase 1/2","brief_title":"Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT04669899 - INNATE","lead_sponsor":"Jounce Therapeutics, Inc.","biomarkers":" EGFR • PD-L1 • ALK • IDH1 • FGFR","pipe":" | ","alterations":" EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation","tags":["EGFR • PD-L1 • ALK • IDH1 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pimivalimab (JTX-4014) • polzastobart (JTX-8064)"],"overall_status":"Completed","enrollment":" Enrollment 190","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 11/28/2023","primary_completion_date":" 11/28/2023","study_txt":" Completion: 11/28/2023","study_completion_date":" 11/28/2023","last_update_posted":"2024-04-09"},{"id":"c92b8794-1c47-49f1-88e3-148924bb13cc","acronym":"BISCAY","url":"https://clinicaltrials.gov/study/NCT02546661","created_at":"2021-01-18T12:19:22.211Z","updated_at":"2024-07-02T16:35:15.193Z","phase":"Phase 1","brief_title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02546661 - BISCAY","lead_sponsor":"AstraZeneca","biomarkers":" HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL","pipe":" | ","alterations":" PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification","tags":["HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-12"},{"id":"72b6e296-999e-4af6-965d-02f44a6823a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039892","created_at":"2021-09-10T16:57:16.515Z","updated_at":"2024-07-02T16:35:21.555Z","phase":"Phase 2","brief_title":"Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT05039892","lead_sponsor":"3D Medicines (Beijing) Co., Ltd.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e segigratinib (3D185)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-01-31"},{"id":"f6882690-81b0-4166-858f-3df0edb58d54","acronym":"","url":"https://clinicaltrials.gov/study/NCT04572295","created_at":"2021-01-18T21:49:54.892Z","updated_at":"2024-07-02T16:35:28.616Z","phase":"Phase 1","brief_title":"A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer","source_id_and_acronym":"NCT04572295","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" HER-2 • ER • FGFR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • exemestane • Tasfygo (tasurgratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 10/09/2020","start_date":" 10/09/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-11-20"},{"id":"ee75280d-fc90-465e-b0a5-f0b3469013da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05176665","created_at":"2022-01-04T13:53:37.122Z","updated_at":"2024-07-02T16:35:35.271Z","phase":"Phase 1/2","brief_title":"EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers","source_id_and_acronym":"NCT05176665","lead_sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","biomarkers":" EGFR • KRAS • BRAF • ALK • NRAS • ROS1 • FGFR • NTRK","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • MET amplification • EGFR amplification • EGFR overexpression","tags":["EGFR • KRAS • BRAF • ALK • NRAS • ROS1 • FGFR • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • MET amplification • EGFR amplification • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bafisontamab (EMB-01)"],"overall_status":"Recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 08/04/2024","primary_completion_date":" 08/04/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-09-29"},{"id":"fc5e8b29-6dcb-4531-a767-ace8038c4ef9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02272998","created_at":"2021-01-18T10:41:33.356Z","updated_at":"2024-07-02T16:35:36.656Z","phase":"Phase 2","brief_title":"Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.","source_id_and_acronym":"NCT02272998","lead_sponsor":"Sameek Roychowdhury","biomarkers":" FLT3 • ABL1 • RET • PDGFRA • FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FLT3 • ABL1 • RET • PDGFRA • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/24/2015","start_date":" 02/24/2015","primary_txt":" Primary completion: 11/17/2022","primary_completion_date":" 11/17/2022","study_txt":" Completion: 11/17/2023","study_completion_date":" 11/17/2023","last_update_posted":"2023-09-18"},{"id":"0dc214cb-e4f0-4eac-bbd1-1e6b414e93b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03220646","created_at":"2021-01-18T15:53:44.589Z","updated_at":"2024-07-02T16:35:43.717Z","phase":"Phase 2","brief_title":"Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors","source_id_and_acronym":"NCT03220646","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • FGFR","pipe":" | ","alterations":" IDH wild-type","tags":["EGFR • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 07/13/2017","start_date":" 07/13/2017","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-07-07"},{"id":"ebd5d4f3-9c51-4862-880f-738277ea8dc8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05216120","created_at":"2022-02-05T18:27:56.347Z","updated_at":"2024-07-02T16:35:44.081Z","phase":"Phase 2","brief_title":"Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas","source_id_and_acronym":"NCT05216120","lead_sponsor":"HonorHealth Research Institute","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2023-07-03"},{"id":"497636a5-3be8-43e7-ab4e-68cdb921e1b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02520141","created_at":"2021-01-18T12:10:49.209Z","updated_at":"2024-07-02T16:35:45.633Z","phase":"Phase 2","brief_title":"Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02520141","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • lexatumumab (ETR2-ST01)"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 12/29/2015","start_date":" 12/29/2015","primary_txt":" Primary completion: 06/29/2022","primary_completion_date":" 06/29/2022","study_txt":" Completion: 06/29/2022","study_completion_date":" 06/29/2022","last_update_posted":"2023-06-15"},{"id":"ab7410d8-2300-42e7-99c4-950787c11580","acronym":"","url":"https://clinicaltrials.gov/study/NCT02872714","created_at":"2021-01-17T17:44:53.147Z","updated_at":"2024-07-02T16:35:52.533Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)","source_id_and_acronym":"NCT02872714","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR3 • FGFR","pipe":" | ","alterations":" FGFR3 mutation • FGFR3 fusion","tags":["FGFR3 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 263","initiation":"Initiation: 01/12/2017","start_date":" 01/12/2017","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 02/01/2022","study_completion_date":" 02/01/2022","last_update_posted":"2023-03-24"},{"id":"646bc9ea-cd2c-4652-ba70-0a8a88e2cb29","acronym":"","url":"https://clinicaltrials.gov/study/NCT04565275","created_at":"2021-01-18T21:48:35.840Z","updated_at":"2024-07-02T16:35:53.319Z","phase":"Phase 1/2","brief_title":"A Study of ICP-192 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04565275","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gunagratinib (ICP-192)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 04/15/2024","study_completion_date":" 04/15/2024","last_update_posted":"2023-03-14"},{"id":"949ede97-fc32-4fe5-8d9c-6dec54d38ea6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03955913","created_at":"2021-01-18T19:28:10.500Z","updated_at":"2024-07-02T16:35:54.777Z","phase":"","brief_title":"A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations","source_id_and_acronym":"NCT03955913","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"],"overall_status":"Completed","enrollment":" Enrollment 3679","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 09/19/2022","primary_completion_date":" 09/19/2022","study_txt":" Completion: 09/19/2022","study_completion_date":" 09/19/2022","last_update_posted":"2023-02-24"}]